Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19Michael A. Thompson, KM Steve Lo, Elizabeth Robilotti et al.|JAMA Oncology|2021Cited by 185
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)Devaki Shilpa Surasi, Morand Piert, Matthias Eiber et al.|European Urology|2023Cited by 90
Diagnostic Performance and Safety of <sup>18</sup> F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)Ashesh B. Jani, Katherine Zukotynski, Gregory Ravizzini et al.|The Journal of Urology|2023Cited by 65
The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate CancerNeil J. Shah, William Oh, Vaibhav G. Patel et al.|JNCI Cancer Spectrum|2022Cited by 11
The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.Vaibhav G. Patel, William Oh, Xiaobo Zhong et al.|Journal of Clinical Oncology|2021Cited by 5